scholarly journals EVASEP: A Noninterventional Study Describing the Perception of Neurologists, Patients, and Caregivers on Caregivers’ Role in the Support of Patients Suffering from Multiple Sclerosis Treated with Subcutaneous Interferon Beta 1a

2016 ◽  
Vol 2016 ◽  
pp. 1-10 ◽  
Author(s):  
Cécile Donzé ◽  
Bruno Lenne ◽  
Anne-Sophie Jean Deleglise ◽  
Christian Kempf ◽  
Yasmine Bellili ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Interferon Beta ◽  
Support Providers ◽  
Effective Care ◽  
Relapsing Remitting ◽  
Support Provider ◽  
Care Package ◽  
Low Levels ◽  
Noninterventional Study

Background. The perception of the role of caregivers for people with multiple sclerosis (MS) is important but poorly studied, particularly in patients with low levels of disability.Objectives. To describe the perceptions of the role of caregivers from the perspective of the caregiver, the patient, and neurologists.Methods. This observational study was conducted in France on patients with relapsing remitting MS treated with subcutaneous (SC) interferon-β-1a (IFN-β-1a) for more than 24 months.Results. Caregiver, patients, and neurologists all considered providing moral support and fighting against the disease as the most important role of the care provider. Moral support was considered significantly more important by caregivers than the patients and neurologists (p=0.002) and caregivers considered their role in helping patients to fight disease more important than did the neurologists (p=0.006). Knowledge of disease and available treatments were less important among support providers than patients (p=0.007andp=0.001).Conclusion. There are many unmet needs in the perception of the role of caregivers for people with MS which need to be addressed to deliver the most effective care package for patients and to support the needs of the support provider.

scholarly journals NLRP3 polymorphisms and response to interferon-beta in multiple sclerosis patients

2017 ◽  
Vol 24 (11) ◽  
pp. 1507-1510 ◽  
Author(s):  
Sunny Malhotra ◽  
Melissa Sorosina ◽  
Jordi Río ◽  
Silvia Peroni ◽  
Luciana Midaglia ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Interferon Beta ◽  
Meta Analysis ◽  
Nlrp3 Gene ◽  
Radiological Criteria ◽  
Pyrin Domain ◽  
Relapsing Remitting ◽  
Multiple Sclerosis Patients

We aimed to investigate whether NLR family, pyrin domain containing 3 (NLRP3) polymorphisms are associated with the response to interferon-beta (IFNβ) in multiple sclerosis (MS) patients. A total of 14 NLRP3 polymorphisms were genotyped in a cohort of 665 relapsing-remitting MS patients recruited across 5 centers and classified into responders and non-responders according to clinical-radiological criteria after 1 year of IFNβ treatment. A meta-analysis failed to demonstrate significant associations between the response to IFNβ and NLRP3 polymorphisms. These findings do not support a role of polymorphisms located in the NLRP3 gene and the response to IFNβ in MS patients.

Chitinase 3-like 1 plasma levels are increased in patients with progressive forms of multiple sclerosis

2011 ◽  
Vol 18 (7) ◽  
pp. 983-990 ◽  
Author(s):  
E Cantó ◽  
F Reverter ◽  
C Morcillo-Suárez ◽  
F Matesanz ◽  
O Fernández ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Interferon Beta ◽  
Clinical Course ◽  
Healthy Controls ◽  
Protein Levels ◽  
Secondary Progressive ◽  
Inflammatory Conditions ◽  
Relapsing Remitting ◽  
Ms Pathogenesis

Background: Chitinase 3-like 1 (CHI3L1) is upregulated in a wide variety of inflammatory conditions. Recent studies have pointed to a role of CHI3L1 in multiple sclerosis (MS) pathogenesis. Objective: The objective of this study was to investigate the role of plasma CHI3L1 in MS clinical course and disease activity and to evaluate the effect of interferon-beta (IFNβ) treatment on protein levels. Methods: Plasma CHI3L1 levels were determined by ELISA in 57 healthy controls (HC), 220 untreated MS patients [66 primary progressive MS patients (PPMS), 30 secondary progressive MS patients (SPMS), and 124 relapsing–remitting MS patients (RRMS), 94 during clinical remission and 30 during relapse], and 32 MS patients receiving IFNβ treatment. A polymorphism of the CHI3L1 gene, rs4950928, was genotyped in 3274 MS patients and 3483 HC. Results: Plasma CHI3L1 levels were significantly increased in patients with progressive forms of MS compared with RRMS patients and HC. CHI3L1 levels were similar between RRMS patients in relapse and remission. A trend towards decreased CHI3L1 levels was observed in IFNβ-treated patients. Allele C of rs4950928 was significantly associated with PPMS patients and with higher plasma CHI3L1 levels. Conclusions: These findings point to a role of CHI3L1 in patients with progressive forms of MS, particularly in those with PPMS.

scholarly journals Induction or aggravation of other immune-mediated disorders by disease-modifying therapy in treatment of multiple sclerosis

2019 ◽  
Author(s):  
Seyed Mohammad Baghbanian ◽  
Mohammad Ali Sahraian
Keyword(s):  
Multiple Sclerosis ◽  
Interferon Beta ◽  
Immunomodulatory Agents ◽  
Disease Modifying Drugs ◽  
Disease Modifying Therapy ◽  
Immune Mediated ◽  
Relapsing Remitting ◽  
Disease Modifying ◽  
Relapsing Remitting Multiple Sclerosis

Interferon beta (IFN-β) and glatiramer acetate (GA) are the primary therapeutic immunomodulatory agents that interfere with relapsing-remitting multiple sclerosis (RRMS), and the most commonly-used drugs as well. Induction or aggravation of other immune-mediated diseases has been reported following INF-β administration. We have reviewed the reported cases to notify the treating physicians about these rare adverse events. Although co-morbid autoimmune disorders have been reported in patients with MS, the pro-inflammatory role of disease-modifying drugs, especially INF-β, could affect and enhance this co-occurrence. Clinical or laboratory autoimmunity histories suggest the use of GA over INF-β as the treatment of choice.

Interferon-beta and disability progression in relapsing-remitting multiple sclerosis

2013 ◽  
Vol 115 ◽  
pp. S65-S69 ◽  
Author(s):  
Jelena Drulovic ◽  
Jelena Kostic ◽  
Sarlota Mesaros ◽  
Irena Dujmovic Basuroski ◽  
Nebojsa Stojsavljevic ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Interferon Beta ◽  
Disability Progression ◽  
Relapsing Remitting ◽  
Remitting Multiple Sclerosis ◽  
Relapsing Remitting Multiple Sclerosis

Cognition in Early Relapsing-Remitting Multiple Sclerosis: Consequences May Be Relative to Working Memory

2013 ◽  
Vol 19 (8) ◽  
pp. 938-949 ◽  
Author(s):  
Lindsay I. Berrigan ◽  
Jo-Anne LeFevre ◽  
Laura M. Rees ◽  
Jason Berard ◽  
Mark S. Freedman ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Working Memory ◽  
Processing Speed ◽  
Cognitive Functions ◽  
Group Membership ◽  
Equation Modeling ◽  
Mediating Role ◽  
Relapsing Remitting ◽  
Disease Stages

AbstractThe Relative Consequence Model proposes multiple sclerosis (MS) patients have a fundamental deficit in processing speed that compromises other cognitive functions. The present study examined the mediating role of processing speed, as well as working memory, in the MS-related effects on other cognitive functions for early relapsing-remitting patients. Seventy relapsing-remitting MS patients with disease duration not greater than 10 years and 72 controls completed tasks assessing processing speed, working memory, learning, and executive functioning. The possible mediating roles of speed and working memory in the MS-related effects on other cognitive functions were evaluated using structural equation modeling. Processing speed was not significantly related to group membership and could not have a mediating role. Working memory was related to group membership and functioned as a mediating/intervening factor. The results do not support the Relative Consequence Model in this sample and they challenge the notion that working memory impairment only emerges at later disease stages. The results do support a mediating/intervening role of working memory. These results were obtained for early relapsing-remitting MS patients and should not be generalized to the broader MS population. Instead, future research should examine the relations that exist at other disease stages. (JINS, 2013, 19, 1–12)

Interferon Beta Use and Disability Prevention in Relapsing-Remitting Multiple Sclerosis

2013 ◽  
Vol 70 (2) ◽  
pp. 248 ◽  
Author(s):  
Benjamin M. Greenberg ◽  
Laura Balcer ◽  
Peter A. Calabresi ◽  
Bruce Cree ◽  
Anne Cross ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Interferon Beta ◽  
Disability Prevention ◽  
Relapsing Remitting ◽  
Remitting Multiple Sclerosis ◽  
Relapsing Remitting Multiple Sclerosis
Sign in / Sign up

Export Citation Format

Share Document